Search Results

Correction: SARS-CoV-2 Virologic Rebound With Nirmatrelvir–Ritonavir Therapy.

Subjects: SARS-CoV-2; COVID-19 treatment; ONLINE comments

• Source: Annals of Internal Medicine. Apr2024, Vol. 177 Issue 4, p547-547. 7p.

Record details

A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2.

• Authors : Paules, Catharine I. (AUTHOR); Wang, Jing (AUTHOR); Tomashek, Kay M. (AUTHOR)

Subjects: COVID-19; NATIONAL Institute of Allergy & Infectious Diseases (U.S.); COVID-19 treatment

• Source: Annals of Internal Medicine. Mar2024, Vol. 177 Issue 3, p343-352. 11p.

Record details

SARS-CoV-2 Virologic Rebound With Nirmatrelvir–Ritonavir Therapy: An Observational Study.

• Authors : Edelstein, Gregory E. (AUTHOR); Boucau, Julie (AUTHOR); Uddin, Rockib (AUTHOR)

Subjects: NATIONAL Institutes of Health (U.S.); COVID-19 treatment; VIRAL transmissionBOSTON (Mass.)

• Source: Annals of Internal Medicine. Dec2023, Vol. 176 Issue 12, p1577-1585. 10p.

Record details

Effectiveness of Nirmatrelvir–Ritonavir Against the Development of Post–COVID-19 Conditions Among U.S. Veterans: A Target Trial Emulation.

• Authors : Ioannou, George N. (AUTHOR); Berry, Kristin (AUTHOR); Rajeevan, Nallakkandi (AUTHOR)

Subjects: VETERANS; COVID-19 pandemic; PULMONARY embolism

• Source: Annals of Internal Medicine. Nov2023, Vol. 176 Issue 11, p1486-1497. 13p.

Record details

Inhaled Fluticasone Furoate for Outpatient Treatment of Covid-19.

• Authors : Boulware, David R.; Lindsell, Christopher J.; Stewart, Thomas G.

Subjects: COVID-19 treatment; FLUTICASONE; COVID-19UNITED States

• Source: New England Journal of Medicine. 9/21/2023, Vol. 389 Issue 12, p1085-1095. 11p.

Record details

Improving COVID-19 Disease Severity Surveillance Measures: Statewide Implementation Experience.

• Authors : Doron, Shira (AUTHOR); Monach, Paul A. (AUTHOR); Brown, Catherine M. (AUTHOR)

Subjects: COVID-19; COVID-19 treatment; HERD immunityMASSACHUSETTS

• Source: Annals of Internal Medicine. Jun2023, Vol. 176 Issue 6, p849-852. 5p. 1 Graph.

Record details

Impact of a clinical pharmacist‐led COVID‐19 treatment consult service in two primary care seniors clinics.

• Authors : Hart, Caitlin (AUTHOR); Linnebur, Sunny A. (AUTHOR); Fixen, Danielle R. (AUTHOR)

Subjects: COVID-19 treatment; COVID-19; EMERGENCY room visits

• Source: JACCP: Journal of the American College of Clinical Pharmacy. Jun2024, Vol. 7 Issue 6, p529-534. 6p.

Record details

Double-blinded, randomised, placebo-controlled trial of convalescent plasma for COVID-19: analyses by neutralising antibodies homologous to recipients’ variants.

• Authors : Khawaja, T.; Kajova, M.; Levonen, I.

Subjects: CONVALESCENT plasma; COVID-19; COVID-19 treatmentWUHAN (China)

• Source: Infectious Diseases. Jun2024, Vol. 56 Issue 6, p423-433. 11p.

Record details

Outcomes and clinical characteristics of the compassionate use of plitidepsin in COVID-19 patients with solid tumours, haematological malignancies or anti-CD20 antibody treatment.

• Authors : Aguareles, Jose (AUTHOR); Villares Fernández, Paula (AUTHOR); Forné, Carles (AUTHOR)

Subjects: COVID-19; DEPSIPEPTIDES; COVID-19 treatment

• Source: Infectious Diseases. Jul2024, Vol. 56 Issue 7, p575-580. 6p.

Record details

Drug Repurposing and Observational Studies: The Case of Antivirals for the Treatment of COVID-19.

• Authors : Hernán, Miguel A. (AUTHOR); del Amo, Julia (AUTHOR)

Subjects: DRUG repositioning; COVID-19 treatment; COVID-19 pandemic

• Source: Annals of Internal Medicine. Apr2023, Vol. 176 Issue 4, p556-560. 5p. 1 Chart.

Record details